The Patients Who Were Told 'There Is Nothing More We Can Do'
The patients whose cases we describe here share one common characteristic before arriving at OPTM: they had each been told, by qualified medical professionals, that their options were exhausted. Surgery was the next step. Or: 'You'll have to learn to live with it.'
We share their stories not as advertising, but as a statement about what is possible when pain is approached as a metabolic problem rather than a structural inevitability.
Case 1 — Mrs. Priya S., 58, Delhi: Bilateral Grade 3 knee osteoarthritis. Scheduled for bilateral total knee replacement. Three years of escalating NSAIDs, two rounds of cortisone injections per knee, physiotherapy for 18 months with diminishing returns. At OPTM assessment: CRP 48 mg/L (reference <5), IL-6 elevated 4x normal, MMP-3 significantly elevated. 42-day protocol commenced. At day 42: CRP 6.2 mg/L, IL-6 within normal range, VAS pain score 8/10 → 1.5/10. Surgery cancelled. At 18-month follow-up: maintained on maintenance protocol, fully functional, no significant pain.
Case 2 — Mr. Rajan K., 45, Kolkata: L4-L5 disc herniation with sciatica, 3-year history. Two epidural injections providing 6-week relief each. Referred for L4-L5 fusion surgery. At OPTM assessment: elevated IL-1β, disc height loss consistent with 15% dehydration. 42-day spinal rehydration protocol. At day 42: disc height restored by 1.4mm on MRI, sciatica resolved, VAS 7/10 → 0.5/10. Fusion surgery not required. At 12-month follow-up: symptom-free, returned to daily running.
Case 3 — Mrs. Anita V., 62, Panchkula: Rheumatoid arthritis, 8-year history on Methotrexate and Sulfasalazine with suboptimal control. DAS28 score 5.2 (high disease activity). At OPTM assessment: anti-CCP 3x upper limit of normal, CRP 32 mg/L. 90-day OPTM protocol alongside maintained DMARD therapy. At day 90: DAS28 2.1 (remission), CRP 4.8 mg/L. DMARDs dose halved in consultation with rheumatologist. At 24-month follow-up: DAS28 1.9, DMARD-free trial commenced.
These cases are drawn from OPTM's documented patient database. The underlying science — metabolic intervention targeting the biochemical drivers of musculoskeletal disease — is the same across all OPTM clinics in Delhi, Kolkata, and Panchkula.
Explore Further
Related Clinical Resources
